Xeris Biopharma Holdings, Inc.

XERS

US98422E1038

Pharmaceuticals

Market Closed - Nasdaq Other stock markets 04:00:00 2024-07-12 pm EDT			5-day change	1st Jan Change
2.355 ^USD	+0.64%		+11.61%	+0.21%

Jul. 08	Xeris Biopharma Appoints John Shannon as CEO	MT
Jul. 08	Xeris Biopharma Holdings, Inc. Announces CEO Changes	CI

Xeris Biopharma Holdings, Inc. Provides Product Revenue Guidance for the Year 2022

March 10, 2022 at 07:00 am EST

Xeris Biopharma Holdings, Inc. provided product revenue guidance for the year 2022. For the year, the company expects net product revenue of $105 million to $120 million.

Latest news about Xeris Biopharma Holdings, Inc.

Xeris Biopharma Appoints John Shannon as CEO	Jul. 08	MT
Xeris Biopharma Holdings, Inc. Announces CEO Changes	Jul. 08	CI
Xeris Biopharma Holdings, Inc. Announces Executive Changes	Jul. 08	CI
Sector Update: Health Care Stocks Higher in Afternoon Trading	May. 30	MT
Xeris Biopharma Says Potential Levothyroxine Injection Preferred Over Oral Formulation; Shares Rise	May. 30	MT
Xeris Biopharma Announces Positive Topline Phase 2 Clinical Data of Its Investigational XeriSol-Formulated Once-Weekly Subcutaneous (SC) Levothyroxine (XP-8121)	May. 30	CI
Transcript : Xeris Biopharma Holdings, Inc., Q1 2024 Earnings Call, May 09, 2024	May. 09
Earnings Flash (XERS) XERIS BIOPHARMA HOLDINGS Reports Q1 Revenue $40.6M, vs. Street Est of $41.8M	May. 09	MT
Xeris Biopharma Holdings, Inc. Provides Revenue Guidance for the Full Year 2024	May. 09	CI
Xeris Biopharma Holdings, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	May. 09	CI
Xeris Biopharma Collaborating With Beta Bionics for Development, Commercialization of Glucagon Product	May. 06	MT
Oppenheimer Initiates Coverage on Xeris Biopharma With Outperform Rating, $5 Price Target	Mar. 28	MT
Xeris Biopharma Holdings, Inc.(NasdaqGS:XERS) added to S&P Pharmaceuticals Select Industry Index	Mar. 17	CI
Transcript : Xeris Biopharma Holdings, Inc., Q4 2023 Earnings Call, Mar 06, 2024	Mar. 06
Earnings Flash (XERS) XERIS BIOPHARMA HOLDINGS Reports Q4 Revenue $44.4M, vs. Street Est of $43.6M	Mar. 06	MT
Xeris Biopharma Holdings, Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2023	Mar. 06	CI
Xeris Biopharma Holdings, Inc. Provides Earnings Guidance for the Year 2024	Mar. 06	CI
Xeris Refinances its $150 Million Senior Secured Term Loan Facility with Hayfin Capital	Mar. 06	CI
North American Morning Briefing : Stock Futures -2-	Mar. 06	DJ
Xeris Biopharma Holdings Seeks Acquisitions	Jan. 11	CI
Transcript : Xeris Biopharma Holdings, Inc. Presents at J.P. Morgan 42nd Annual Healthcare Conference 2024, Jan-11-2024 12:00 PM	Jan. 11
US Equity Markets Close Higher Wednesday as Investors Await Inflation Data	Jan. 10	MT
Sector Update: Health Care Stocks Gain Late Afternoon	Jan. 10	MT
Xeris Biopharma Shares Rise on Licensing Agreement With Amgen	Jan. 10	MT
Xeris Biopharma Shares Climb 12% on Amgen License Agreement	Jan. 10	DJ

Chart Xeris Biopharma Holdings, Inc.

Duration

Period

More charts

Xeris Biopharma Holdings, Inc. is a biopharmaceutical company, which is focused on improving patientsâ lives by developing and commercializing products across a range of therapies. It has three commercial products. Gvoke is a ready-to-use, liquid-stable glucagon for the treatment of severe hypoglycemia. Recorlev is a cortisol synthesis inhibitor approved for the treatment of endogenous hypercortisolemia in adult patients with Cushingâs syndrome for whom surgery is not an option or has not been curative. Keveyis is the first therapy approved in the United States to treat hyperkalemic, hypokalemic, and related variants of Primary Periodic Paralysis (PPP). It also has a pipeline of development programs to bring new products forward using its proprietary formulation science, XeriSol and XeriJect. Its product candidate XP-8121, which is designed to be a once-weekly, small-volume, subcutaneous injection that bypasses the gastrointestinal tract and could avoid many therapeutic complications.

Sector

Pharmaceuticals

Calendar

2024-08-06 - Q2 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Ratings for Xeris Biopharma Holdings, Inc.

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

2.355 USD

Average target price

4.9 USD

Spread / Average Target

+108.07%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

	1st Jan change	Capi.
XERIS BIOPHARMA HOLDINGS, INC.	+0.21%	349M
ELI LILLY AND COMPANY	+62.66%	854B
NOVO NORDISK A/S	+40.42%	636B
JOHNSON & JOHNSON	-4.37%	361B
MERCK & CO., INC.	+17.16%	324B
ABBVIE INC.	+9.87%	301B
ASTRAZENECA PLC	+15.66%	247B
ROCHE HOLDING AG	+4.21%	230B
NOVARTIS AG	+17.90%	228B
AMGEN INC.	+14.86%	177B

Other Pharmaceuticals